Transcatheter Atrial Septal Defect Device Closure - A 2.5 Years Single Center Study

Document Type : Original Article

Authors

The Department of Pediatrics, Faculty of Medicine, Assiut University, Assiut, Egypt

Abstract

Abstract
Background: Atrial septal communications account for approximately 6-10% of congenital heart defects, with an incidence of 1 in 1,500 live births. The atrial septal defect (ASD) is among the most common acyanotic congenital cardiac lesions, occurring in 0.1% of births and accounting for 30-40% of clinically important intracardiac shunts.
Transcatheter device closure is advised for all symptomatic patients and also for asymptomatic patients with a Qp: Qs ratio of at least 2:1 or those with right ventricular enlargement. The timing for elective closure is usually after the 1st yr and before entry into school. Closure carried out at open heart surgery is associated with a mortality rate of <1%. Repair is preferred during early childhood because surgical mortality and morbidity are significantly greater in adulthood.
Aim of Study: Is to evaluate 2.5 years experience in transcatheter device closure of secundum atrial septal defect at the Pediatric Cardiology Unit, Assiut University Children Hospital.
Patients and Methods: The study was conducted on 62 patients [56 (90.4%) children and 6 (9.6%) adults] who underwent transcatheter secundum ASD device closure, at Pediatric Cardiology Unit of Assiut University Children Hospital from March 2014 till September 2016.
Results: Transcatheter closure of secundum ASD in chil-dren adolescents and adults has a high success rate (98.3%) regarding the efficacy (successful closure of the defect without residual shunt) and safety (no death or major complications as cerebral embolism, cardiac tamponade, device embolization or dislodgement requiring open cardiac surgery and infectious endocarditis) during procedure, immediate and short to midterm follow-up.
Conclusion: Transcatheter closure of secundum ASD in children adolescents and adults has a high success rate (98.3%) regarding the efficacy (successful closure of the defect without residual shunt) and safety (no death or major complications as cerebral embolism, cardiac tamponade, device embolization or dislodgement requiring open cardiac surgery and infectious endocarditis) during procedure, immediate and short to midterm follow-up.

Keywords